Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?

Diabetes Therapy - United States
doi 10.1007/s13300-019-0663-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cardiovascular Outcome Trials in Diabetes: What Have We Learnt?

Trends in Urology & Men's Health
2018English

Cardiologists' Approach to Managing Cardiovascular Risk in Patients With Type 2 Diabetes

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Type 2 Diabetes and Cardiovascular Risk Factors

Current Medical Research and Opinion
Medicine
2011English

Cardiovascular Risk in Patients With Type 2 Diabetes

CMAJ
Medicine
2005English

Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk

Journal of Managed Care Pharmacy
2007English

Cardiovascular Outcome Trials of Diabetes Drugs: Lessons Learned

Journal of Clinical Investigation
Medicine
2018English

Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2018English

Cardiovascular Risk Reduction: What Do Recent Trials With Rosuvastatin Tell Us?

Advances in Therapy
MedicinePharmacology
2009English

Lessons From a Cardiovascular Outcome Trial With Liraglutide in Type 2 Diabetes

Journal of Diabetes Investigation
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy